Delving into the Latest Updates on Docetaxel with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BEIZRAY, DEP® docetaxel, Docetaxel Hydrate

+ [62]

Target

Tubulin

Action

inhibitors

Mechanism

Tubulin inhibitors

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Early Stage Breast CarcinomaGastroesophageal junction adenocarcinomaMetastatic castration-resistant prostate cancer+ [37]

Inactive Indication

AdenocarcinomaAdenocarcinoma of EsophagusAdenocarcinoma of prostate+ [111]

Originator Organization

Sanofi

Active Organization

Sanofi Winthrop Industrie SA

Sandoz Group AG

AstraZeneca PLC

+ [25]

Inactive Organization

Sanofi

Aventis Pharmaceuticals, Inc.

Novartis Pharmaceuticals Canada, Inc.

+ [29]

License Organization

Sanofi (China) Investment Co. Ltd.The General Hospital Corp.

Lumos Pharma, Inc.

+ [10]

Drug Highest PhaseApproved

First Approval Date

European Union (27 Nov 1995),

Breast CancerHead and Neck NeoplasmsNon-Small Cell Lung Cancer+ [2]

RegulationAccelerated Approval (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC43H55NO15

InChIKeyYWKYKORYUFJSCV-XKIQGVRMSA-N

CAS Registry148408-66-6

The goal of this clinical trial is to find out if taking natural products green tea and quercetin along with docetaxel chemotherapy improves the therapy of advanced prostate cancer, i.e., metastatic castration-resistant prostate cancer (mCRPC). It will also learn about the safety of this combination.
Researchers will compare green tea plus quercetin to a placebo (a look-alike substance that contains no drug) in combination with docetaxel to see if green tea and quercetin works to improve the therapeutic effect of docetaxel.

Start Date01 Mar 2026

Sponsor / Collaborator

Charles Drew University of Medicine & Science

[+2]

JPRN-UMIN000021079

/ CompletedNot ApplicableIIT

Upfront abiraterone and docetaxel administration in patients with high-risk metastatic hormone-naive prostate cancer - UFAD in mHNPC

Start Date31 Jan 2026

Sponsor / Collaborator-

100 Clinical Results associated with Docetaxel

Login to view more data

100 Translational Medicine associated with Docetaxel

Login to view more data

100 Patents (Medical) associated with Docetaxel

Login to view more data

27,746

Literatures (Medical) associated with Docetaxel

01 Jan 2026·MARINE POLLUTION BULLETIN

Shifts in microbial metabolism for algal-derived organic matter utilization under dynamic oxygen conditions

Article

Author: Jiao, Nianzhi ; Li, Yuguo ; Chen, Xiaoxia ; Shi, Quan ; Tang, Kai ; Dong, Changjie ; Chen, Quanrui

The increase prevalence of hypoxic zones worldwide requires a comprehensive understanding of how marine organic carbon cycles under these conditions to assess their impact on global carbon cycles and ecosystem health. This study, conducted within the seasonal hypoxia zone of the Yangtze River Estuary, investigates the effects of deoxygenation on the microbial utilization of algal-derived organic carbon. Culture experiments and molecular analyses revealed remarkable adaptability in the composition and metabolic pathways of heterotrophic bacterial communities in response to hypoxic conditions. Findings demonstrate that while initial rates of dissolved organic carbon (DOC) utilization are reduced under hypoxia, the consumption over time is comparable to conditions of deoxygenation gradually. High-throughput 16S rDNA sequencing highlighted notable shifts in microbial community dynamics, with a consistent increase in the roles of key heterotrophic bacterial groups such as Rhodobacteraceae, Flavobacteriaceae, and Vibrionaceae in the transformation of organic carbon under reduced oxygen conditions. Importantly, hypoxia was found to induce more complex patterns observed in the transformations of dissolved organic sulfur. The depleted DOC molecules were predominantly composed of CHON and CHO. Under hypoxic conditions, unique microbial organic modules emerged, displaying positive correlations with dissolved organic sulfur (DOS) molecules, primarily involving the Shewanellaceae and Bacteroidetes. This research reveals specific microbial responses and metabolic mechanisms involved in the transformation of algal-derived organic carbon under hypoxic conditions. These findings improve our understanding of organic carbon cycling processes in hypoxic waters and offer new insights for future research on microbially driven carbon cycling.

01 Jan 2026·JOURNAL OF AFFECTIVE DISORDERS

Real-world pharmacovigilance analysis of depression associated with antineoplastic agents

Article

Author: Shang, Jinlu ; Chen, Weiyi ; Wang, Ke ; Guo, Ling ; Zhou, Meiling ; Li, Ruixiao ; Tao, Chao

Cancer remains a major global health threat. Although antineoplastic agents have significantly improved survival outcomes, growing evidence indicates that they may also induce neuropsychiatric adverse events (AEs), particularly depressive symptoms. Such effects can severely compromise patients' quality of life and adherence to therapy. However, this issue has not been systematically evaluated. In this study, we investigated depression-related AEs submitted to the FDA Adverse Event Reporting System from Q1 2004 to Q4 2024. We included reports involving antineoplastic agents (Anatomical Therapeutic Chemical [ATC] code L01) with oncology-related indications and excluded those with concomitant antidepressant use (ATC N06A) for depression-related indications. Disproportionality analyses were performed using the Reporting Odds Ratio (ROR) and the Bayesian Confidence Propagation Neural Network. A total of 211 antineoplastic agents potentially associated with depression and suicide/self-injury were identified, and class-specific risks were evaluated. Most reports involved female patients, and 56.3 % concerned individuals older than 45 years. Protein kinase inhibitors and other antineoplastics exhibited the strongest associations. Notably, significant signals were observed for docetaxel (ROR = 3.7; IC025 = 1.8), palbociclib (ROR = 2.03; IC025 = 0.98), and ibrutinib (ROR = 1.83; IC025 = 0.83). These signals call for heightened clinical vigilance and may inform safer prescribing. Prospective, multicenter studies integrating pharmacovigilance, mechanistic, and clinical data are needed to guide personalized strategies aimed at improving patient outcomes.

31 Dec 2025·Adipocyte

FLOT chemotherapy treatment affects adipocyte’s lipid metabolism: an in vitro study

Article

Author: Richard, Ruddy ; Brac de la Perrière, Jean ; Malpuech-Brugère, Corinne ; Pinel, Alexandre ; Bacoeur-Ouzillou, Ophélie ; Guerrier, Lisa ; Touron, Julianne ; Gagnière, Johan

Cachexia is a complex syndrome that is often associated with cancer. Chemotherapy, one of the main cancer treatments, worsens weight loss in cancer-induced cachexia. In this context, it is thought that fat loss precedes muscle loss, and that alterations in adipose tissue are associated with tumours. However, the effect of cancer treatment on adipose tissue is not well understood. This study aimed to evaluate the impact of chemotherapy alone on mature 3T3-L1 adipocytes to identify the mechanisms contributing to adipose tissue alteration. The murine cell line 3T3-L1, a model of mature adipocytes, was used in this study. After differentiation, cells were treated for 48 h with a chemotherapy cocktail called FLOT composed of 5-fluorouracil, leucovorin, oxaliplatin and docetaxel at two concentrations (FLOT 1X and 0.1X). The control group was treated with the vehicle of the chemotherapy cocktail. Viability, mitochondrial function and dynamics, lipid metabolism, and cellular stress were also evaluated. FLOT 1X chemotherapy significantly reduced viability of mature 3T3-L1 cells and inhibited lipid accumulation. Interestingly, while FLOT 1X treatment downregulated lipogenesis markers, FLOT 0.1X treatment upregulated some of them. Although, the treatment showed no effect on mitochondrial respiration or density, it significantly increased expression of oxidative stress and inflammation markers in adipocytes.This in vitro study provides the first evidence of FLOT chemotherapy's direct effects on healthy mature adipocytes. The results demonstrate significant treatment-induced reductions in cell viability along with dysregulation of both lipogenic and lipolytic pathways. These findings elucidate previously unrecognized mechanisms underlying adipose tissue dysfunction in cancer cachexia.

1,120

News (Medical) associated with Docetaxel

03 Dec 2025

·www.relmada.com

Relmada Therapeutics Announces Presentation of NDV-01 Phase 2 Data at the Society for Urologic Oncology

Poster highlights 6-month follow-up data from the ongoing Phase 2 trial of NDV-01 in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Relmada plans to advance NDV-01, a sustained release intravesical formulation of gemcitabine/docetaxel (Gem/Doce), into Phase 3 studies in two indications in H1 2026 Company is focused on high-risk NMIBC and intermediate-risk NMIBC, representing about 80% of new NMIBC cases every year, or about 54,000 people in the United States CORAL GABLES, Fla., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system indications, today announced that the previously disclosed 6-month follow-up data from the ongoing Phase 2 study of NDV-01, a sustained release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce), in development for non-muscle invasive bladder cancer (NMIBC) will be presented in a poster at the Society of Urologic Oncology 26th Annual Meeting (SUO 2025). The poster (#143) will be presented by Yair Lotan, MD, Chairman of Relmada’s Clinical Advisory Board, on Thursday, December 4th at 2:30 PM MT in Phoenix, AZ. Raj S. Pruthi, MD, Chief Medical Officer-Oncology of Relmada Therapeutics, noted, “We believe NDV-01 has the opportunity to transform the treatment of NMIBC by providing patients and physicians with a potential bladder-sparing, in-office, ready-to-use, safe, effective and durable, best-in-class therapy. We are on track to initiate the Phase 3 program in H1 2026, building on the encouraging, recently announced 9-month data, showing a 92% complete response (CR) rate at any time point, and encouraging recent FDA discussions, which provide us with a well-defined registrational strategy in two distinct indications in NMIBC with limited treatment options.” The Society of Urologic Oncology 26th Annual Meeting Information: Title: Prospective Open-Label Study to Evaluate the Safety and Efficacy of Intravesical Sustained-Release Gemcitabine Docetaxel combination (NDV-01) in High-Risk NMIBC: Update with 6-month Complete Response Data Poster Number: #143 Date and Time: Thursday, December 4th at 2:30 PM MT A copy of the poster will be available on the Events section of the Relmada website after the session. To review the an overview of the 9-month data and FDA discussions, click here. About NDV-01 NDV-01 is a sustained-release, intravesical formulation of gemcitabine and docetaxel (Gem/Doce), in development for the treatment of non-muscle invasive bladder cancer. It is designed to enable Gem/Doce bladder retention and gradual drug release over 10 days. The formulation creates a soft matrix that enhances local exposure while minimizing systemic toxicity. The NDV-01 formulation is a ready to use, convenient to administer in-office in less than 10 minutes, and does not require anesthesia or specialized equipment. It is protected by patents through 2038. About the Phase 2 Study The Phase 2 study (NCT06663137) is an open-label, single-arm, single-center study evaluating the safety and efficacy of NDV-01 in patients with HG-NMIBC. Patients are treated with NDV-01 in a biweekly induction phase, follow by monthly maintenance for up to one year, with regular assessments via cystoscopy, cytology, and biopsy, as indicated. The primary efficacy endpoints are safety and complete response rate (CRR) at 12 months, and secondary efficacy endpoints are duration of response (DOR) and event free survival (EFS). About NMIBC NMIBC represents 75-80% of all bladder cancer cases and is associated with high recurrence (50–80% over 5 years). With over 744,000 prevalent cases in the U.S. and limited treatment options, the market opportunity is significant. NDV-01 has the potential to serve as a frontline or salvage therapy and could be applicable across multiple NMIBC subtypes. About Relmada Therapeutics, Inc. Relmada Therapeutics is a clinical-stage biotechnology company focused on developing transformative therapies for oncology and central nervous system conditions. Its lead candidates, NDV-01 and sepranolone, are advancing through mid-stage clinical development with the potential to address significant unmet needs. For more information, visit www.relmada.com Forward-Looking Statements: The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “if”, “may”, “expects”, “anticipates”, “believes”, “will”, “will likely result”, “will continue”, “plans to”, “potential”, “promising”, and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential for Relmada’s product candidates to progress, including the potential for Phase 2 NDV-01 data to continue to deliver positive results supporting further development, potential for clinical trials to deliver statistically and/or clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure of planned or ongoing preclinical and clinical studies to demonstrate expected results, potential failure to continue to secure FDA agreement on the regulatory path for NDV-01 and/or sepranolone, or that future NDV-01 and/or sepranolone clinical results will be acceptable to the FDA, failure to secure adequate NDV-01 and/or sepranolone drug supply, the Company’s cash runway and sufficiency of the Company’s cash resources and uncertainties inherent in estimating the Company’s cash runway, future expenses and other financial results, including its ability to fund future operations, including clinical trials, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein are not a complete list. Investor Contact: Brian Ritchie LifeSci Advisors britchie@lifesciadvisors.com Media Inquiries: Corporate Communications media@relmada.com Released December 3, 2025

Phase 2Phase 3ASCO

02 Dec 2025

·www.businesswire.com

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC

MUNICH & SAN FRANCISCO--(BUSINESS WIRE)--CatalYm today announced that the first patient has been dosed in the randomized Phase 2b GDFATHER‑NSCLC‑02 (GDF‑15 Antibody‑MediaTed‑Human‑Effector‑T‑Cell Relocation) trial (NCT07246863). The trial evaluates the company’s lead anti-GDF-15 antibody visugromab as a second-line treatment in patients with metastatic non-squamous non-small cell lung cancer (nsq NSCLC) who have progressed following initial systemic treatment including an approved immune checkpoint inhibitor. The trial will assess multiple treatment strategies combining visugromab with an anti-PD-1 antibody and the chemotherapy docetaxel, including a chemo-free regimen. Standard-of-care chemotherapy alone will serve as the control arm. The trial consists of a safety run-in followed by a randomized phase evaluating visugromab in the different combination regimen settings. Visugromab is a humanized, monoclonal antibody that targets Growth Differentiation Factor-15 (GDF-15), a tumor-derived cytokine known to drive immune suppression and resistance to anti-PD-(L)1 therapies. In the exploratory Phase 1/2a GDFATHER trial (NCT04725474), visugromab demonstrated encouraging anti-tumor activity when combined with an anti-PD-1 antibody in advanced-stage, anti-PD-(L)1 relapsed/refractory NSCLC patients, demonstrating deep and durable responses, with a median duration of response of 32.2 months and a favorable safety profile. In addition to its ability to restore immune activation, visugromab also showed potential to alleviate cancer cachexia, a severe condition limiting treatment tolerability and responsible for 20-40% of cancer deaths.1 “The decision to evaluate visugromab in second-line nsq NSCLC, in addition to the first-line setting, was driven by the strength of our Phase 1/2a data in heavily pretreated patients, where we observed deep and durable responses well beyond those typically seen with other therapies in this setting,” said Sujata Rao, MD, Chief Medical Officer at CatalYm. “By neutralizing GDF-15, a key driver of immune suppression, visugromab may overcome resistance, restore responsiveness to immunotherapy and extend the benefit of anti-PD-1 agents. Its additional potential to mitigate cancer cachexia and support tolerance to chemotherapies and other anti-cancer regimens offers a distinct advantage in this difficult-to-treat population.” “We are expanding visugromab’s development into key settings where immune resistance severely limits treatment options,” said Scott Clarke, Chief Executive Officer at CatalYm. “Second-line nsq NSCLC is a particularly challenging indication with limited benefit from current standard-of-care. This trial builds on the compelling rationale for GDF-15 neutralization and is part of our late-stage development program to deliver visugromab’s potential to patients in urgent need of better solutions.” The randomized, multi-arm Phase 2b GDFATHER-NSCLC-02 trial will enroll approximately 131 patients across multiple sites in the US, EU and Switzerland. Following the safety run-in, patients will be randomized into one of four treatment arms: Visugromab + anti-PD-1 inhibitor + chemotherapy Visugromab + anti-PD-1 inhibitor (chemo-free) Visugromab (at lower dose) + anti-PD-1 inhibitor + chemotherapy Chemotherapy alone (control) The primary endpoint of the study is objective response rate (ORR) defined as the percentage of participants with a best overall response (BOR) of complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Secondary endpoints include duration of response (DOR), progression-free survival (PFS), overall survival (OS), participant weight course over time and safety-related measures. About NSCLC Lung cancers remain the leading cause of cancer-related mortality globally and non-small cell lung cancers (NSCLCs) account for approximately 87% of the 210,000 annual lung cancer diagnoses in the US2. Five-year survival rates in the US for non-squamous NSCLC are low: 12.8% for adenocarcinoma and 5.1% for large-cell carcinoma3. 70-85% of NSCLC patients either exhibit primary resistance to PD-1 blockade or develop acquired resistance to immunotherapy4, emphasizing the need for innovative approaches to overcome immunotherapy resistance. About Visugromab Visugromab is a monoclonal antibody that neutralizes Growth Differentiation Factor-15 (GDF-15), a locally acting immunosuppressant produced by tumors which fosters resistance and drives cachexia in people with cancer. Neutralizing GDF-15 with visugromab reverses key cancer resistance mechanisms to reinstate an efficient anti-tumor response by re-enabling immune cell activation, proliferation and induction of interferon-γ. In addition, visugromab also mitigates cancer cachexia, a severe condition affecting a significant number of advanced cancer patients by inhibiting the activation of the GFRAL pathway in the brainstem, a key driver of weight loss and appetite suppression in cancer patients. About CatalYm CatalYm is developing visugromab, a first-in-class anti-GDF-15 antibody, in solid tumors and cachexia. In its first-in-human Phase 1/2a study, visugromab demonstrated durable anti-tumor efficacy with long-lasting objective responses in relapsed and refractory metastatic solid tumor patients in combination with anti-PD-1 treatment. In addition, data from the same study demonstrated that visugromab can significantly counteract the effects of cachexia in these patients. This data was published in Nature and presented at the International Conference on Sarcopenia, Cachexia & Wasting Disorders. CatalYm is now advancing visugromab into multiple Phase 2b studies including first-line metastatic non-squamous NSCLC (NCT07098988), second-line metastatic non-squamous NSCLC (NCT07246863) and cachexia (NCT07112196). Founded in 2016 and based in Munich, Germany and San Francisco, USA, CatalYm is backed by leading international investors including Canaan Partners, Omega Funds, Bioqube Ventures, Forbion, Jeito Capital, Brandon Capital, Gilde Healthcare, Novartis Venture Fund, Vesalius, Bayern Kapital, BioGeneration Ventures, and Coparion. 1 Fearon K. et al. Lancet Oncol. 2011;12(8):489–495. 2 American Cancer Society, Key Statistics for Lung Cancer, 2025: https://www.cancer.org/cancer/types/lung-cancer/about/key-statistics.html, retrieved on Aug. 06, 2025 3 https://seer.cancer.gov/ 4 Mariniello A, Borgeaud M, Weiner M, Frisone D, Kim F, Addeo A. Primary and Acquired Resistance to Immunotherapy with Checkpoint Inhibitors in NSCLC: From Bedside to Bench and Back. BioDrugs. 2025 Mar;39(2):215-235. doi: 10.1007/s40259-024-00700-2. Epub 2025 Feb 15. PMID: 39954220; PMCID: PMC11906525.

ImmunotherapyPhase 2Clinical Result

01 Dec 2025

·pmlive.com

AstraZeneca’s Imfinzi receives FDA approval for gastric and gastro-oesophageal cancers

AstraZeneca’s Imfinzi (durvalumab), in combination with standard of care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin and docetaxel), has been approved by the US FDA to treat adult patients with resectable, early-stage and locally advanced gastric and gastro-oesophageal junction (GEJ) cancers. The approval follows a Priority Review from the FDA, and is based on results from the MATTERHORN phase 3 trial, which enrolled participants in 176 centres across 20 countries. In an interim analysis, patients receiving the Imfinzi/FLOT combination had a 29% reduced risk of disease progression, recurrence or death versus chemotherapy alone. An estimated 78.2% of patients treated with the Imfinzi/FLOT combination were event-free at one year, compared to 74% in the FLOT-only arm. In the final analysis, results showed that treatment with the Imfinzi/FLOT combination reduced the risk of death by 22% compared to chemotherapy alone. An estimated 69% of patients treated with the Imfinzi/FLOT combination were alive at three years, compared with 62% in the FLOT-only arm. Gastric cancer is the fifth most common cancer in the world; it is also the fifth-highest cause of cancer deaths. In 2022, nearly one million new patients were diagnosed with gastric cancer, and approximately 660,000 deaths were reported globally from the disease. GEJ is a type of gastric cancer that occurs where the oesophagus connects to the stomach. In 2024, there were around 43,000 patients in the US, EU and Japan with early-stage and locally advanced gastric or GEJ cancer. Recurrence and relapse are common in patients with resectable gastric cancer and survival rates remain poor, with less than half of gastric cancer patients alive at five years. Imfinzi is already approved, in combination with chemotherapy, as a treatment for both small cell and non-small cell lung cancers, as well as bladder cancer and endometrial cancer, under specific circumstances. Dave Fredrickson, executive vice president of the Oncology Haematology Business Unit at AstraZeneca, said: “This approval ushers in a new clinical paradigm for patients with early gastric and gastroesophageal junction cancers, with Imfinzi plus FLOT delivering a durable survival benefit that increases over time. As the third US approval for a perioperative Imfinzi-based regimen, this milestone further validates the perioperative approach and underscores our focus on bringing novel treatments to early-stage cancers where cure is the goal.”

Clinical ResultPhase 3Drug ApprovalPriority ReviewAccelerated Approval

100 Deals associated with Docetaxel

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D07866	Docetaxel	L01CD02	DB01248

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Early Stage Breast Carcinoma	European Union	Accord Healthcare SLU	22 May 2012
Early Stage Breast Carcinoma	Iceland	Accord Healthcare SLU	22 May 2012
Early Stage Breast Carcinoma	Liechtenstein	Accord Healthcare SLU	22 May 2012
Early Stage Breast Carcinoma	Norway	Accord Healthcare SLU	22 May 2012
Gastroesophageal junction adenocarcinoma	European Union	Fresenius Kabi Deutschland GmbH	22 May 2012
Gastroesophageal junction adenocarcinoma	Iceland	Fresenius Kabi Deutschland GmbH	22 May 2012
Gastroesophageal junction adenocarcinoma	Liechtenstein	Fresenius Kabi Deutschland GmbH	22 May 2012
Gastroesophageal junction adenocarcinoma	Norway	Fresenius Kabi Deutschland GmbH	22 May 2012
Metastatic castration-resistant prostate cancer	European Union	Fresenius Kabi Deutschland GmbH	22 May 2012
Metastatic castration-resistant prostate cancer	European Union	Accord Healthcare SLU	22 May 2012
Metastatic castration-resistant prostate cancer	Iceland	Accord Healthcare SLU	22 May 2012
Metastatic castration-resistant prostate cancer	Iceland	Fresenius Kabi Deutschland GmbH	22 May 2012
Metastatic castration-resistant prostate cancer	Liechtenstein	Accord Healthcare SLU	22 May 2012
Metastatic castration-resistant prostate cancer	Liechtenstein	Fresenius Kabi Deutschland GmbH	22 May 2012
Metastatic castration-resistant prostate cancer	Norway	Accord Healthcare SLU	22 May 2012
Metastatic castration-resistant prostate cancer	Norway	Fresenius Kabi Deutschland GmbH	22 May 2012
Metastatic gastric adenocarcinoma	European Union	Accord Healthcare SLU	22 May 2012
Metastatic gastric adenocarcinoma	Iceland	Accord Healthcare SLU	22 May 2012
Metastatic gastric adenocarcinoma	Liechtenstein	Accord Healthcare SLU	22 May 2012
Metastatic gastric adenocarcinoma	Norway	Accord Healthcare SLU	22 May 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-sensitive prostate cancer	Phase 3	United Kingdom	Novartis AG	11 Jun 2024
Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	08 Jun 2023
Hormone-dependent prostate cancer	Phase 3	Austria	Bayer AG	16 May 2023
Hormone-dependent prostate cancer	Phase 3	Germany	Bayer AG	16 May 2023
Advanced Malignant Solid Neoplasm	Phase 3	India	Zhuhai Beihai Biotechnology Co., Ltd.	29 Apr 2021
Solid tumor	Phase 3	India	Zhuhai Beihai Biotechnology Co., Ltd.	29 Apr 2021
Circulating Neoplastic Cells	Phase 3	United Kingdom	Sanofi	11 Jan 2017
Metastatic Prostate Carcinoma	Phase 3	United Kingdom	Sanofi	11 Jan 2017
HER2 Positive Breast Cancer	Phase 3	United States	Hoffmann-La Roche, Inc.	14 Mar 2016
HER2 Positive Breast Cancer	Phase 3	China	Hoffmann-La Roche, Inc.	14 Mar 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04854499 (ELEVATE HNSCC, CTgov)	Phase 2	Squamous cell carcinoma of head and neck metastatic	193	Platinum+Magrolimab+Pembrolizumab+5-FU (Safety Run-in Cohort 1: Magrolimab + Pembrolizumab + Platinum + 5-FU)	torreanotu = wyznbmnjtl tpytvhmoaw (mkflyrkckl, cdtxemmvjd - qgixevkooc) View more	-	19 Nov 2025
				Magrolimab+Docetaxel (Safety Run-in Cohort 2: Magrolimab + Docetaxel)	torreanotu = doibfxlzlr tpytvhmoaw (mkflyrkckl, eiqwwofcol - aazceawljx) View more
NCT04396535 (CTgov)	Phase 2	Advanced Lung Non-Small Cell Carcinoma	10	Bintrafusp Alfa+Docetaxel (Arm I (Docetaxel, Bintrafusp Alfa))	ukfjuqtbux(anvuyurtfv) = yfrgpmwryd lnnlnstzhq (eyibhaafhl, axsoyrilqs - venzivguve) View more	-	17 Nov 2025
				Docetaxel (Arm II (Docetaxel))	ukfjuqtbux(anvuyurtfv) = owrjxstuaa lnnlnstzhq (eyibhaafhl, wvydmjfnwk - egpqnrcjms) View more
ESMO2025	Not Applicable	Metastatic human epidermal growth factor 2 positive carcinoma of breast First line HER2-positive	127	Docetaxel, trastuzumab, and pertuzumab (THP)	vzzzryjiby(qjoqpboaze) = hymssstiss ateekrmkdu (ibxtpvadca ) View more	Positive	17 Oct 2025
				Docetaxel, trastuzumab, and pertuzumab (THP) (SUVmax >10)	vzzzryjiby(qjoqpboaze) = zuulcpmwab ateekrmkdu (ibxtpvadca ) View more
JPRN-jRCT1041220029 (HIPPOCRATES, ESMO2025)	Phase 2	Oropharyngeal Neoplasms Neoadjuvant p16 immunohistochemistry	32	Neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (NAC-TPF)	dvtbqdakpa(gxxpcicdxw) = olmfhxkoaw jwzhbdbkbb (udmekttdig, 49.58 - 79.38)	Positive	17 Oct 2025
EUCTR2020-000770-21-FR (GORTEC 2019-01, ESMO2025)	Phase 2	Locally Advanced Head and Neck Squamous Cell Carcinoma	105	mTPF (T and P 40 mg/m d1, F 1000 mg/m/d d1→d2, 6 cycles q2w)	ltehsoburi(mzabvtqkpp) = iwacpjlcrb wtunqsnawp (grvgaemjup, 64.7 - 84.2) View more	Positive	17 Oct 2025
				TPF (T and P 75 mg/m at day (d) 1, F 750 mg/m/d d1→d5, 3 cycles every 3 weeks (q3w))	ltehsoburi(mzabvtqkpp) = poasnbgumo wtunqsnawp (grvgaemjup, 60.6 - 88.5) View more
ESMO2025	Not Applicable	Locally Advanced Lung Non-Small Cell Carcinoma	1,453	Docetaxel monotherapy	eoadczgdol(ddvcfvmgid) = ukiqtyjdaq euhumtylwn (lpcwrwpcyj, 6.6 - 9.6)	Negative	17 Oct 2025
				Docetaxel + nintedanib (Cohort A)	eoadczgdol(ddvcfvmgid) = thoegkgspp euhumtylwn (lpcwrwpcyj, 5.1 - 10.5)
NCT00268476 (STAMPEDE, ESMO2025)	Phase 3	Hormone-dependent prostate cancer	6,292	ADT alone (M0)	pbptizuuma(idszlxrone) = frmwqhpywq yqwlrvkzzq (dliuqnfjsz, 12 - 22) View more	Negative	17 Oct 2025
				ADT alone (M1)	pbptizuuma(idszlxrone) = pbohggwvya yqwlrvkzzq (dliuqnfjsz, 5 - 10)
NCT03421288 (ESMO2025)	Phase 3	Locally Advanced Gastric Carcinoma	216	FLOT (docetaxel-oxaliplatin-5FU)	pioynkjxkk(lubdcwuvpd) = ikjglvmyqx siecqyublm (dxqhaukrdp ) View more	Positive	17 Oct 2025
				CAPOX (Capecitabine-Oxaliplatin)	pioynkjxkk(lubdcwuvpd) = betzhmkrzs siecqyublm (dxqhaukrdp ) View more
JPRN-jRCTs041210023 (ESMO2025)	Phase 2	Locally Advanced Esophageal Squamous Cell Carcinoma Neoadjuvant	41	Neoadjuvant docetaxel, oxaliplatin plus S-1	jjvfhdpvtf(izucvuchgj) = vnimcrbbji krrmfoepkb (ilvfejipgq ) View more	Positive	17 Oct 2025
NCT06780085 (KEYMAKER-U01, ESMO2025)	Phase 2	metastatic non-small cell lung cancer	240	R-DXd 5.6 mg/kg Q3W	nvdptgljrz(qezjpuycjc) = wdrrhjzhmy cmkwvypjgz (gseqzxaqhq )	Positive	17 Oct 2025
				I-DXd 12 mg/kg Q3W	nvdptgljrz(dkyroehllm) = wbfmmbjuhe hhwuadaise (ggdormwoaz ) View more